Hypoparathyroidism Treatment Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 0.63 Billion |
| Market Size (2030) | USD 1.49 Billion |
| CAGR (2025 - 2030) | 4.00% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Hypoparathyroidism Treatment Market Analysis
The Hypoparathyroidism Treatment Market size is estimated at USD 0.63 billion in 2025, and is expected to reach USD 1.49 billion by 2030, at a CAGR of 4% during the forecast period (2025-2030).
Factors such as the rising incidence of hypoparathyroid disorders and the growing demand for innovative treatments are set to propel market growth during the forecast period. For example, an April 2024 article in the Endocrinology and Metabolism journal highlighted that using rhPTH(1-84) or PTH(1-34) as a substitute for the missing hormone in hypoparathyroidism treatment reduced dependence on traditional therapies. Palopegteriparatide, a prodrug, guarantees a steady release of PTH(1-34), designed to keep parathyroid hormone (PTH) levels stable within the physiological range for 24 hours. Hence, the increasing adoption of these new therapies is anticipated to fuel market growth.
Moreover, the rise of conferences and events focusing on treatment advancements in hypoparathyroidism is likely to bolster market growth. For instance, the 25th European Congress of Endocrinology, held in May 2023, delved into case studies in which ADH1-related hypoparathyroidism patients need meticulous management through conventional therapy to mitigate risks like hypercalciuria and nephrolithiasis, even if this doesn't tackle the condition's root cause. The conference also provided a succinct overview of hypoparathyroidism and discussed management guidelines for both established and emerging treatments. Thus, these events are poised to catalyze advancements in hypoparathyroidism treatments, boosting market growth.
In conclusion, with the influx of advanced treatment modalities and a rise in conferences spotlighting hypoparathyroidism treatment trends, this market is set to lead growth. Yet, potential adverse reactions and side effects from hypoparathyroid treatments could pose challenges to this growth trajectory.
Hypoparathyroidism Treatment Market Trends
Vitamin D Analogue Segment is Expected to Witness Growth Over the Forecast Period
Parathyroid hormone (PTH) is essential for converting 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol), within the kidneys. Current treatments for hypoparathyroidism (HPT) predominantly involve high doses of vitamin D, either in the form of ergocalciferol (D2) or cholecalciferol (D3), with a more frequent emphasis on the active metabolite, 1,25-dihydroxyvitamin D3 (calcitriol). The standard initiation dose for calcitriol typically ranges from 0.25 to 0.5 μg, administered bi-daily. Given the rising adoption of Vitamin D3 supplements among hypoparathyroidism patients and the surge in product launches, this trend is poised to bolster segment growth in the coming years.
In the past, patients with hypoparathyroidism were often termed as having "vitamin D resistance," a label stemming from their requirement for unusually high vitamin D doses to maintain normal calcium levels. The global surge in product launches and the widespread availability of vitamin D3 products are anticipated to propel segment growth in the future. For example, in February 2024, Cadila Pharmaceuticals introduced its aqueous formulations of cholecalciferol. Standard treatment protocols typically involve the administration of calcium and vitamin D supplements. Notably, this new product demonstrated superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to the conventional oil-based cholecalciferol preparations.
In conclusion, the effective management of hypoparathyroidism is heavily reliant on vitamin D3 supplementation, which leverages both the parent compound and its 25-hydroxylated metabolite. When combined with active vitamin D analogs and calcium, this strategy ensures optimal calcium homeostasis for patients, further fueling the segment's growth in the coming years.
North America is Expected to Witness a Significant Growth Over the Forecast Period
North America is poised to see significant market growth, driven by an uptick in pipeline assets for hypoparathyroid treatments and supportive government initiatives in the region. Moreover, universities and government bodies have rolled out pivotal guidelines for hypoparathyroidism treatment, presenting fresh avenues for key players and bolstering the segment's growth trajectory. For instance, in August 2024, the University of California (UCF) unveiled new guidelines from the Second International Workshop on the Evaluation and Management of Hypoparathyroidism. These guidelines, rooted in the latest evidence, focus on preventing, diagnosing, and managing hyperparathyroidism in the United States, offering valuable insights for community-based clinical endocrinologists to maintain high care standards.
Factors such as key product launches, a dense concentration of market players, robust pipeline assets, and a strong manufacturer presence are propelling the growth of the hypoparathyroidism treatment market in the United States. For instance, in May 2023, Amolyt Pharma kicked off its Phase 3 clinical trial for eneboparatide, a long-acting parathyroid hormone 1 (PTH1) receptor agonist aimed at hypoparathyroidism patients. This move came after Amolyt secured End-of-Phase 2 guidance from the FDA. Given the robust pipeline assets in the United States, their anticipated approvals are set to further fuel market growth in the coming years.
Hypoparathyroidism Treatment Industry Overview
The hypoparathyroidism treatment market is semi-consolidated due to the presence of several companies operating globally and regionally. The key players are involved in various strategic activities such as partnerships, collaborations, product launches, etc., among others. The competitive landscape includes an analysis of a few international and local companies. A few of the key competitors are EnteraBio Ltd., Amgen Inc., Ascendis Pharma A/S, F. Hoffmann-La Roche AG, Zhejiang NHU Co., Ltd., and Teva Pharmaceuticals, among others.
Hypoparathyroidism Treatment Market Leaders
-
F. Hoffmann-La Roche Ltd
-
Teva Pharmaceutical Industries Ltd.
-
Amgen Inc.
-
Zhejiang NHU Co., Ltd.
-
EnteraBio Ltd.
- *Disclaimer: Major Players sorted in no particular order
Hypoparathyroidism Treatment Market News
- August 2024: Ascendis Pharma A/S received the United States (U.S) Food & Drug Administration (FDA) approval for its YORVIPATH (palopegteriparatide; developed as TransCon PTH) for treating hypoparathyroidism in adults. YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is administered once daily and is designed to ensure continuous exposure to released PTH throughout the 24-hour dosing period.
- May 2024: The United States Food and Drug Administration (FDA) awarded fast-track designation to eneboparatide, an experimental drug aimed at treating hyperparathyroidism. The phase 3 Calypso trial is investigating Eneboparatide.
Hypoparathyroidism Treatment Industry Segmentation
As per the scope of the report, hypoparathyroidism, a rare endocrine disorder, arises from dysfunction of the parathyroid glands, leading to a deficiency in parathyroid hormone. This deficiency subsequently causes hypocalcemia, hyperphosphatemia, and heightened neuromuscular irritability.
The hypoparathyroidism treatment market is segmented by product type, route of administration, end-user, and geography. By product type, the market is segmented into parathyroid hormone, vitamin D analogue, calcium supplements, and others. By route of administration, the market is segmented into oral and parenteral. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online sales. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Product Type | Parathyroid Hormone Replacement | ||
| Vitamin D Analogue | |||
| Calcium Supplements | |||
| Others (Thiazide Diuretics, Magnesium Supplements) | |||
| By Route of Administration | Oral | ||
| Parenteral | |||
| By Distribution Channel | Hospital Pharmacies | ||
| Retail Pharmacies | |||
| Online Platforms | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Parathyroid Hormone Replacement |
| Vitamin D Analogue |
| Calcium Supplements |
| Others (Thiazide Diuretics, Magnesium Supplements) |
| Oral |
| Parenteral |
| Hospital Pharmacies |
| Retail Pharmacies |
| Online Platforms |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Hypoparathyroidism Treatment Market Research FAQs
How big is the Hypoparathyroidism Treatment Market?
The Hypoparathyroidism Treatment Market size is expected to reach USD 0.63 billion in 2025 and grow at a CAGR of 4% to reach USD 1.49 billion by 2030.
What is the current Hypoparathyroidism Treatment Market size?
In 2025, the Hypoparathyroidism Treatment Market size is expected to reach USD 0.63 billion.
Who are the key players in Hypoparathyroidism Treatment Market?
F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Amgen Inc., Zhejiang NHU Co., Ltd. and EnteraBio Ltd. are the major companies operating in the Hypoparathyroidism Treatment Market.
Which is the fastest growing region in Hypoparathyroidism Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Hypoparathyroidism Treatment Market?
In 2025, the North America accounts for the largest market share in Hypoparathyroidism Treatment Market.
What years does this Hypoparathyroidism Treatment Market cover, and what was the market size in 2024?
In 2024, the Hypoparathyroidism Treatment Market size was estimated at USD 0.60 billion. The report covers the Hypoparathyroidism Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Hypoparathyroidism Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Hypoparathyroidism Treatment Industry Report
Statistics for the 2025 Hypoparathyroidism Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hypoparathyroidism Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
